Fred M. Powell Net Worth

The estimated Net Worth of Fred M Powell is at least $4.25 Миллион dollars as of 12 November 2020. Mr Powell owns over 16,400 units of Antares Pharma Inc stock worth over $3,613,739 and over the last 8 years he sold ATRS stock worth over $0. In addition, he makes $636,393 as Exec. VP & CFO at Antares Pharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Powell ATRS stock SEC Form 4 insiders trading

Mr has made over 3 trades of the Antares Pharma Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 16,400 units of ATRS stock worth $46,740 on 12 November 2020.

The largest trade he's ever made was buying 130,000 units of Antares Pharma Inc stock on 9 June 2017 worth over $362,700. On average, Mr trades about 13,689 units every 80 days since 2016. As of 12 November 2020 he still owns at least 646,465 units of Antares Pharma Inc stock.

You can see the complete history of Mr Powell stock trades at the bottom of the page.

Mr. Fred M. Powell biography

Fred M. Powell is the Exec. VP & CFO at Antares Pharma Inc.

What is the salary of Mr Powell?

As the Exec. VP & CFO of Antares Pharma Inc, the total compensation of Mr Powell at Antares Pharma Inc is $636,393. There are 1 executives at Antares Pharma Inc getting paid more, with Robert F. Apple having the highest compensation of $1,003,646.

How old is Mr Powell?

Mr Powell is 60, he's been the Exec. VP & CFO of Antares Pharma Inc since . There are 1 older and 3 younger executives at Antares Pharma Inc. The oldest executive at Antares Pharma Inc is Dr. Peter Sadowski, 73, who is the Sr. VP of Technology Portfolio & Intellectual Property.

What's Mr Powell's mailing address?

Fred's mailing address filed with the SEC is 100 Princeton South #300, Ewing Township, NJ 08628, USA.

Insiders trading at Antares Pharma Inc

Over the last 12 years, insiders at Antares Pharma Inc have traded over $29,755,747 worth of Antares Pharma Inc stock and bought 910,400 units worth $1,278,090 . The most active insiders traders include James E Deerfield Mgmt L.P...., James E Deerfield Mgmt L.P.... и Jacques Gonella. On average, Antares Pharma Inc executives and independent directors trade stock every 28 days with the average trade being worth of $751,296. The most recent stock trade was executed by Anton Gueth on 8 July 2021, trading 100,000 units of ATRS stock currently worth $429,000.

What does Antares Pharma Inc do?

Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), Covis Pharma (Covis), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma's FDA-approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA® (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals.

Complete history of Mr Powell stock trades at Antares Pharma Inc

Antares Pharma Inc executives and stock owners

Antares Pharma Inc executives and other stock owners filed with the SEC include:

• Robert F. Apple,
  CEO, Pres & Director
• Fred M. Powell,
  Exec. VP & CFO
• Peter J. Graham,
  Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• Greg Defilippis,
  Sr. VP of Device Bus. & Alliances
• Dr. Jonathan S. Jaffe,
  Interim EVP, Pharmaceutical R&D and Chief Medical Officer
• Dr. Peter Sadowski,
  Sr. VP of Technology Portfolio & Intellectual Property
• Edward Tykot,
  Sr. VP of Corp. Bus. Devel.
• Tram Bui,
  VP of Corp. Communications & Investor Relations
• Keith Muckenhirn,
  Principal Accounting Officer, VP of Fin. & Corp. Controller
• Patrick Madsen,
  Sr. VP of Operations
• Anton Gueth,
  Director
• Robert P Jr Roche,
  Director
• Thomas J Garrity,
  Director
• Fred M Powell,
  Executive Vice President & CFO
• Leonard S Jacob,
  Director
• Marvin Samson,
  Director
• James E Fickenscher,
  Senior Vice President & CFO
• James E Deerfield Mgmt L.P....,
  
• Jacques Gonella,
  Director
• Peter J Graham,
  See Remarks
• James Patrick Tursi,
  EVP, Chief Medical Officer
• Peter Greenleaf,
  Director
• Karen L. Smith,
  Director
• James E Deerfield Mgmt L.P....,
  
• Kaushik J Dave,
  Executive Vice President
• Jennifer Evans Stacey,
  SVP, General Counsel & Secty
• James E Deerfield Mgmt L.P....,
  
• Paul K Wotton,
  President and CEO
• Eamonn P Hobbs,
  Director
• Peter C Richardson,
  See Remarks
• Carmen B Volkart,
  Director
• Robert F Apple,
  President and CEO